Foghorn Therapeutics (FHTX) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[2], including 1 Phase 1[1].
No Form 4 insider filings for FHTX were recorded at the SEC in the past 30 days[3].
FHTX is tracked by BiotechSigns with a current catalyst score of 36/100 and grade D. The page summarizes 0 active signals, including 0 PDUFA, 0 insider buying, and 0 clinical trial signals, with data refreshed on 2026-06-03.
Foghorn Therapeutics (FHTX) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[2], including 1 Phase 1[1].
No Form 4 insider filings for FHTX were recorded at the SEC in the past 30 days[3].